Bio Path Holdings Stock Performance
| BPTH Stock | USD 0.07 0.01 11.67% |
The firm shows a Beta (market volatility) of 3.61, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Path will likely underperform. Bio Path Holdings right now shows a risk of 9.84%. Please confirm Bio Path Holdings treynor ratio and the relationship between the semi variance and period momentum indicator , to decide if Bio Path Holdings will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bio Path Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Bio Path is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Bio |
Bio Path Relative Risk vs. Return Landscape
If you would invest 9.00 in Bio Path Holdings on October 28, 2025 and sell it today you would lose (2.30) from holding Bio Path Holdings or give up 25.56% of portfolio value over 90 days. Bio Path Holdings is currently generating 0.0019% in daily expected returns and assumes 9.8436% risk (volatility on return distribution) over the 90 days horizon. In different words, 88% of otc stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Path Target Price Odds to finish over Current Price
The tendency of Bio OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.07 | 90 days | 0.07 | about 73.28 |
Based on a normal probability distribution, the odds of Bio Path to move above the current price in 90 days from now is about 73.28 (This Bio Path Holdings probability density function shows the probability of Bio OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the otc stock has the beta coefficient of 3.61 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bio Path will likely underperform. Additionally Bio Path Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Bio Path Price Density |
| Price |
Predictive Modules for Bio Path
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bio Path Holdings. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bio Path's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bio Path Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bio Path is not an exception. The market had few large corrections towards the Bio Path's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bio Path Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bio Path within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 3.61 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.0026 |
Bio Path Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bio Path for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bio Path Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bio Path Holdings had very high historical volatility over the last 90 days | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Bio Path Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bio OTC Stock often depends not only on the future outlook of the current and potential Bio Path's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bio Path's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 478 K | |
| Cash And Short Term Investments | 1.1 M |
Bio Path Fundamentals Growth
Bio OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Path, and Bio Path fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio OTC Stock performance.
| Return On Equity | -11.6 | |||
| Return On Asset | -1.94 | |||
| Current Valuation | 531.06 K | |||
| Shares Outstanding | 5.77 M | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 2.33 X | |||
| EBITDA | (15.76 M) | |||
| Cash And Equivalents | 17.02 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 113 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (11.54 M) | |||
| Earnings Per Share | (8.34) X | |||
| Total Asset | 3.22 M | |||
| Retained Earnings | (107.61 M) | |||
| Current Asset | 9.59 M | |||
| Current Liabilities | 937 K | |||
About Bio Path Performance
By evaluating Bio Path's fundamental ratios, stakeholders can gain valuable insights into Bio Path's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Path has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Path has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Things to note about Bio Path Holdings performance evaluation
Checking the ongoing alerts about Bio Path for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Bio Path Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Path Holdings had very high historical volatility over the last 90 days | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Bio Path's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Path's stock is overvalued or undervalued compared to its peers.
- Examining Bio Path's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Path's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Path's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Bio Path's otc stock. These opinions can provide insight into Bio Path's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio OTC Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |